# Bluesail Medical to acquire Swiss heart valve company NVT for RMB 1.39 billion

Bluesail Medical Co., Ltd. announced its intention to acquire 100% equity interest in New Valve Technology (NVT), a Swiss developer and manufacturer of transcatheter interventional heart valves, with a total consideration of RMB 1.39 billion for the acquisition and subsequent capital injection. The acquisition will expand Bluesail's portfolio in cardiovascular high-value consumables.

- Type: Acquisition
- Announced: 2019-08-02
- Where: Switzerland
- Value: $197.0M (1.39B CNY)
- Status: announced
- Products: transcatheter interventional heart valves, TAVR system
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Bluesail Medical](https://endata.com/companies/41101.md) (acquirer)
- [New Valve Technology](https://endata.com/companies/41102.md) (target)

## Sources

- [vcbeathealth.com](https://www.vcbeathealth.com/article/47523), 2019-08-04: "On the evening of August 2, Bluesail Medical Co., Ltd. announced its intention to acquire 100% equity interest in New Valve Technology (NVT), a Swiss developer and manufacturer of transcatheter interventional heart valves, with a total consideration of RMB 1.39 billion for the acquisition and subseq"
- [vcbeathealth.com](https://www.vcbeathealth.com/article/29654), 2019-08-05: "Bluesail Medical Co., Ltd. announced its intention to acquire 100% equity interest in New Valve Technology, a Swiss research, development, and manufacturing enterprise specializing in transcatheter interventional cardiac valves."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.